Can a daily capsule boost good vaginal bacteria? new study investigates

NCT ID NCT07715058

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This trial investigates whether taking a daily food supplement called Hifas Intima for 12 weeks can change the types and amounts of bacteria living in the vagina of healthy women aged 18 to 45. The supplement contains mushroom extract, herbs, probiotics, and vitamins. Researchers measure changes in vaginal bacteria, pH, and overall vaginal health, and track any side effects. All participants receive the supplement; there is no placebo group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a food supplement containing mushroom extract, herbs, probiotics, and vitamins
What this could lead to
If it works, this could point toward a dietary supplement that supports vaginal health by promoting beneficial bacteria.
What could go wrong
This is a small, early study with no placebo group, so results may be due to chance or natural variation. The supplement is not a treatment for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Jun 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 18 to 45 years * Able and willing to provide written informed consent, participate in the study, and follow the study supplementation schedule and procedures * No symptoms, or only nonspecific symptoms not attributed to a diagnosed vaginal infection Exclusion Criteria: * Unexplained vaginal bleeding * Suspected or diagnosed cancer * Known intolerance, allergy, or hypersensitivity to any component of Hifas Intima Oral * An immunosuppressive disorder or human immunodeficiency virus infection * Current use of probiotics by any route of administration * A diagnosed specific vaginal infection or current treatment for a vaginal infection * A poorly controlled chronic noncommunicable disease, such as diabetes mellitus, Hashimoto thyroiditis, or heart disease * Pregnancy or planning to become pregnant * Premature menopause

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Microbiota are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Instituto Palacios, Salud y Medicina de la Mujer

    Madrid, Madrid, 28009, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.